Literature DB >> 69269

Short-term antithyroid drug therapy for the thyrotoxicosis of Graves's disease.

M A Greer, H Kammer, D J Bouma.   

Abstract

We investigated whether thyrotoxic patients treated with short-term antithyroid therapy would achieve prolonged remissions. Thirty-one previously untreated and nine previously treated patients with thyrotoxic Graves's disease received a single daily dose of methimazole or propylthiouracil. The drug was stopped at, or shortly after, the time they became euthyroid. Twelve of the 31 previously untreated patients remained in remission for 29 +/- 3.5 months (mean +/- S.E.) after treatment for 4.5 +/- 0.3 months. Four of the nine previously treated have remained in remission of 13.0 +/- 2.1 months after treatment for 3.0 +/- 0.3 months. Of various possibilities analyzed, only a small goiter at the onset of therapy and tri-iodothyronine toxicosis were significantly favorable prognostic indicators that a remission would be maintained. The lasting remission rate is as good when antithyroid drugs are stopped as soon as the patient is euthyroid as when they are continued for one year or more.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 69269     DOI: 10.1056/NEJM197707282970401

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  16 in total

1.  Management of patients with diffuse toxic goitre in Ireland, a country with low iodine intake.

Authors:  A Smith; T J McKenna
Journal:  Ir J Med Sci       Date:  1992-10       Impact factor: 1.568

2.  Remission of Graves' disease with hyperthyroidism by a combination of glucocorticoids and antithyroid drugs.

Authors:  S A Peter
Journal:  J Natl Med Assoc       Date:  1991-03       Impact factor: 1.798

3.  Determination of thyroid stimulating immunoglobulins (TSI) during the course of Graves' disease. A reliable indicator for remission and persistence of this disease?

Authors:  H Schleusener; R Finke; P Kotulla; K W Wenzel; H Meinhold; H D Roedler
Journal:  J Endocrinol Invest       Date:  1978-04       Impact factor: 4.256

4.  Thyroglobulin, thyrotropin and thyrotropin binding inhibiting immunoglobulins assayed at the withdrawal of antithyroid drug therapy as predictors of relapse of Graves' disease within one year.

Authors:  J N Talbot; F Duron; R Féron; P Aubert; G Milhaud
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

Review 5.  Stopping and restarting medications in the perioperative period.

Authors:  R Cygan; H Waitzkin
Journal:  J Gen Intern Med       Date:  1987 Jul-Aug       Impact factor: 5.128

6.  Simple and reliable method for predicting the remission of Graves' disease: revised triiodothyronine-suppression test, indexed by serum thyroxine.

Authors:  N Takasu; H Akamine; I Komiya; T Yamada
Journal:  J Endocrinol Invest       Date:  1995-04       Impact factor: 4.256

7.  Are antithyroid drugs immunosuppressive?

Authors:  P Kendall-Taylor
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-18

8.  Single daily dose methimazole treatment of hyperthyroidism.

Authors:  D J Bouma; H Kammer
Journal:  West J Med       Date:  1980-01

9.  Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission.

Authors:  R V García-Mayor; C Páramo; R Luna Cano; L F Pérez Mendez; J C Galofré; A Andrade
Journal:  J Endocrinol Invest       Date:  1992-12       Impact factor: 4.256

Review 10.  Clinical pharmacokinetics of antithyroid drugs.

Authors:  J P Kampmann; J M Hansen
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.